FORMULATION AND EVALUATION OF ETODOLAC NIOSOMES BY MODIFIED ETHER INJECTION TECHNIQUE

Ejiogu Deborah Chioma

doi:10.22270/ujpr.v1i1.R1

Ejiogu Deborah Chioma Department of human physiology, Ahmadu Bello University, Zaria Kaduna, Nigeria.

10.22270/ujpr.v1i1.R1

Keywords:

Etodolac, niosomes, surfactants, cholesterol, modified ether injection method, in-vitro release, stability studies

Abstract

Objectives: Niosomes are non-ionic surfactant based multilamellar or unilamellar vesicles with aqueous solution of solute that is enclosed by a membrane. Etodolac is an indole acetic acid derivative with half-life of 4 to 7hrs. It is used for the treatment of Rheumatoid arthritis. Whenever used orally, it has many systemic side effects, so it is not preferred orally. The aim of present study was to develop niosomes of Etodolac to avoid all drawbacks associated with it like first pass metabolism and side effects.

Methods: In present study four niosomes formulations of Etodolac were successfully developed by modified ether injection technique using different nonionic surfactant i.e. Span 20, Span 40, Tween 20, Tween 40 and cholesterol. Formulations were evaluated for different parameters like particle size, entrapment efficiency, in-vitro release, stability studies.

Results: Niosomes formulations of batch N3 shows maximum mean particle diameter i.e. 2.46 µm. The entrapment efficiency of the niosomes was between 66.52-78.32%. The entrapment efficiency was found to be higher with the batch N4 (78.32%). The cumulative percent drug release after 10 hrs of the Etodolac niosomes in between 40.59-78.55%. 68.5% for N1, 50.49% for N2, 40.59 for N3 and 78.55 for N4. Accelerated stability studies for 12 weeks revealed that the Etodolac niosomes formulations of batch N4 were stable at up to 45⁰C.

Conclusion: Study concludes that Etodolac can be delivered by niosomes dosage form effectively and all limitations associated with it can be avoided.

Peer Review History:

Article received on- 6 August; Revised 10 September; Accepted 8 October; Available online 15 November 2016

Academic Editor:

Dr. A.A. Mgbahurike, University of Port Harcourt, Nigeria, amaka_mgbahurike@yahoo.com

Received file: Reviewer's Comments:

Average Peer review marks at initial stage: 4.5/10

Average Peer review marks at publication stage: 7.5/10

Reviewer(s) detail:

Dr. Barkat Ali Khan, Kampala International University , Uganda, barki.gold@gmail.com

Prof. Dr. Kapil Kumar, Global Institute of Pharmaceutical Education and Research,
Kashipur, US Nagar, Uttarakhand, India, kapil5november@gmail.com